- Home
- CWEN vs BLCO Comparison
CWEN vs BLCO Comparison
Compare CWEN & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CWEN
- BLCO
- Stock Information
- Founded
- CWEN 2012
- BLCO 1853
- Country
- CWEN United States
- BLCO Canada
- Employees
- CWEN N/A
- BLCO N/A
- Industry
- CWEN Electric Utilities: Central
- BLCO Ophthalmic Goods
- Sector
- CWEN Utilities
- BLCO Health Care
- Exchange
- CWEN Nasdaq
- BLCO Nasdaq
- Market Cap
- CWEN 3.7B
- BLCO 4.3B
- IPO Year
- CWEN 2013
- BLCO 2022
- Fundamental
- Price
- CWEN $32.40
- BLCO $14.04
- Analyst Decision
- CWEN Strong Buy
- BLCO Hold
- Analyst Count
- CWEN 4
- BLCO 13
- Target Price
- CWEN $35.75
- BLCO $15.83
- AVG Volume (30 Days)
- CWEN 909.6K
- BLCO 845.2K
- Earning Date
- CWEN 07-31-2025
- BLCO 07-30-2025
- Dividend Yield
- CWEN 5.28%
- BLCO N/A
- EPS Growth
- CWEN 20.79
- BLCO N/A
- EPS
- CWEN 0.79
- BLCO N/A
- Revenue
- CWEN $1,406,000,000.00
- BLCO $4,829,000,000.00
- Revenue This Year
- CWEN $8.32
- BLCO $6.97
- Revenue Next Year
- CWEN $10.84
- BLCO $5.48
- P/E Ratio
- CWEN $40.76
- BLCO N/A
- Revenue Growth
- CWEN 9.08
- BLCO 11.94
- 52 Week Low
- CWEN $24.22
- BLCO $10.45
- 52 Week High
- CWEN $32.76
- BLCO $21.69
- Technical
- Relative Strength Index (RSI)
- CWEN 57.86
- BLCO 73.74
- Support Level
- CWEN $31.36
- BLCO $12.02
- Resistance Level
- CWEN $32.76
- BLCO $14.32
- Average True Range (ATR)
- CWEN 0.76
- BLCO 0.45
- MACD
- CWEN -0.04
- BLCO 0.20
- Stochastic Oscillator
- CWEN 78.18
- BLCO 90.78
About CWEN Clearway Energy Inc. Class C
Clearway Energy Inc is a publicly-traded energy infrastructure investor with a focus on investments in clean energy and owner of modern, sustainable and long-term contracted assets across North America. The company segments its operations into Flexible Generation, renewables and Corporate divisions.
About BLCO Bausch + Lomb Corporation
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.